Mohit Patel -- Disruptive Diner: Nano Possibilities
20
Mohit B. Patel The next generation of Gene Delivery
-
Upload
openly-disruptive -
Category
Technology
-
view
278 -
download
1
description
Presentation from 10/15/13 on innovative startup producing cost effective nano particle kits to get large amounts of DNA into cells without damaging them. Genetix Fusion LLC founder Mohit Patel explains how nanotech makes this possible and the enormous time and cost problems they're able to address. Join OpenlyDisruptive.org for live access to more disruptive innovation events.
Transcript of Mohit Patel -- Disruptive Diner: Nano Possibilities
Mohit B. Patel
The next generation of Gene Delivery
Macro Micro Nano
Millionth (10-‐6)
Red Blood Cell 8 micrometer
Billionth (10-‐9)
DNA 2nm wide
Human Being 6 feet tall
What is Nano?
Nanotechnology
Energy Nanomedicine Nanosensors
Broad range of applica<ons
Genetic Material
Tissue
Cell
Chromosome DNA
Body
Gene
Genetic Disorders
Illness caused by an abnormality in an individuals DNA/gene.
Gene Delivery
Gene Expression
Research applications: Genetic disorders, gene therapy, protein production, functional genomics, disease diagnostics and
agriculture crop enhancement
Gene Delivery
Gene Delivery
Transfection: Laboratory procedure to delivery foreign DNA into host cells.
Microinjec5on
Physical methods
Electropora5on Gene gun
Advantage: Can transfer large DNA molecules Disadvantage: Highly cytotoxic and expensive
Biological methods
Advantage: Stable transfec<on Disadvantage: High risk and <me consuming
Nanotubes
Chemical methods
Calcium phosphate Lipids
Advantage: Good efficiency Disadvantage: Cytotoxic and limited gene<c informa<on
Limitations of Existing Products
11
• Toxic to cells
• Limited size (kilobases, kb)
• Poor efficiency
• Time consuming
• Inconsistent results
• Costly
$6000 and 30 days / year for
each scientist
“Transfection market clamors for silver bullet.”
Solution: Janus Transfection Kit™
12
Janus Transfection Kit™ utilizes a new class of chemical reagent for DNA transformation and transfection.
New Class = non-lipid, non-viral and non-dendrimer based transfection reagent
Janus Transfection Kit™
Proprietary Platform Technology
STEP 1 STEP 2 STEP 3
Janus Transfection Reagent™
Efficiency: Janus Transfection Kit™ Bacteria Yeast
0.00%
50.00%
100.00%
Janus Transfection Reagent™
Control
Mammalian cells
0 10 20 30 40 50 60
Janus Transfection Reagent™
Control
Nu
mb
er o
f ce
lls
tran
sfom
ed
Plants
0 10 20 30 40 50 60
Janus Transfection Reagent™
Promega's Product
Col
ony
form
ing
un
its
0 100 200 300 400 500 600
Janus Transfection Reagent™
Standard Reagent
Col
ony
form
ing
un
its
Competitive Advantages
15
Company DNA Size Toxicity Cell Versatility Price In-House <7kb High Low $ 413
Invitrogen ~9-12kb High High $ 485 Sigma Aldrich ~11kb Low Medium $ 333
Promega ~7-10kb Low Medium $ 440 Qiagen ~9-12kb Medium Medium $ 288
Genetix Fusion
>20kb None Very High $ 350
Janus Transfection Kit™ will save each researcher an estimated 65% of cost and 50% of time.
Broad range of applications
Solution: Janus Transfection Kit™
Enables use of larger DNA
High efficiency
Non-mutagenic and non-cytotoxic
Transfection Market
$13.4 Billion market DNA and RNA delivery
$346 Million
Genetix Fusion accessible market
Academia 68% ($235 M) Pre-packaged kits 75% ($259 M)
Critical Milestones
Alpha prototype
tested
Provisional patent
Genetix Fusion founded
Beta prototype
Initial funding raised
May 2012
January 2014
January 2015
Strategic distribution
partner
1% Market (~5500 units)
January 2018
4% Market (~28000 units)
Establish operations
Controlled market release
Launch first product
PCT application
Today
Now Seeking
1. Academic researchers for beta testing
2. Collaborative opportunities
3. Distribution partner
4. Seed stage investment
